胸心外科指南

订阅

MedSci主页 / 所有栏目 / 胸心外科指南

2018 STS/SCA/AmSECT临床实践指南：心肺转流术期间的抗凝作用

2018-01-20 美国胸外科医师学会 Anesth Analg. 2018 Feb;126(2):413-424.

心肺转流术体外循环抗凝

2018年，美国胸外科医师学会(STS)、美国心血管麻醉医师协会(SCA)联合美国体外技术学会(AmSECT)共同发布了心肺转流术期间的抗凝指南。指南主要推荐内容涉及启动和维持心肺转流术死亡肝素剂量及监测，肝素禁忌以及肝素替代品，心脏手术抗凝逆转。

中文标题：

2018 STS/SCA/AmSECT临床实践指南：心肺转流术期间的抗凝作用

英文标题：

The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines—Anticoagulation During Cardiopulmonary Bypass

发布机构：

美国胸外科医师学会

发布日期：

2018-01-20

简要介绍：

2018年，美国胸外科医师学会(STS)、美国心血管麻醉医师协会(SCA)联合美国体外技术学会(AmSECT)共同发布了心肺转流术期间的抗凝指南。指南主要推荐内容涉及启动和维持心肺转流术死亡肝素剂量及监测，肝素禁忌以及肝素替代品，心脏手术抗凝逆转。

 

拓展指南：与心肺相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 STS/SCA/AmSECT临床实践指南：心肺转流术期间的抗凝作用)] GetToolGuiderByIdResponse(projectId=1, id=469951c0015ae6c2, title=2018 STS/SCA/AmSECT临床实践指南：心肺转流术期间的抗凝作用, enTitle=The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines—Anticoagulation During Cardiopulmonary Bypass, guiderFrom=Anesth Analg. 2018 Feb;126(2):413-424., authorId=null, author=, summary=2018年，美国胸外科医师学会(STS)、美国心血管麻醉医师协会(SCA)联合美国体外技术学会(AmSECT)共同发布了心肺转流术期间的抗凝指南。指南主要推荐内容涉及启动和维持心肺转流术死亡肝素剂量及监测，肝素禁忌以及肝素替代品，心脏手术抗凝逆转。 , cover=, journalId=null, articlesId=null, associationId=78, associationName=美国胸外科医师学会, associationIntro=null, copyright=0, guiderPublishedTime=Sat Jan 20 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>2018年，美国胸外科医师学会(STS)、美国心血管麻醉医师协会(SCA)联合美国体外技术学会(AmSECT)共同发布了心肺转流术期间的抗凝指南。指南主要推荐内容涉及启动和维持心肺转流术死亡肝素剂量及监测，肝素禁忌以及肝素替代品，心脏手术抗凝逆转。 </P> <P> </P>拓展指南：<strong>与<font color=red>心肺</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=68c7a1c001539e0b" title="成人体外心肺复苏专家共识" target=_blank>成人体外心肺复苏专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=f59701c00153a6f1" title="2017 拉丁美洲共识：儿童心肺复苏术" target=_blank>2017 拉丁美洲共识：儿童心肺复苏术</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=a06ca1c00152916a" title="2017年美国心脏协会儿童基础生命支持及心肺复苏质量的重点更新" target=_blank>2017年美国心脏协会儿童基础生命支持及心肺复苏质量的重点更新</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=58c901c0015290e9" title="2017年美国心脏协会关于成人基本生命支持和心肺复苏质量的重点更新" target=_blank>2017年美国心脏协会关于成人基本生命支持和心肺复苏质量的重点更新</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=9dbb51c00152891c" title="2017国际复苏联合会共识：心肺复苏和心血管急救治疗推荐要点" target=_blank>2017国际复苏联合会共识：心肺复苏和心血管急救治疗推荐要点</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E5%BF%83%E8%82%BA" target=_blank>有关心肺更多指南</a></ul>, tagList=[TagDto(tagId=50515, tagName=心肺转流术), TagDto(tagId=2735, tagName=体外循环), TagDto(tagId=1207, tagName=抗凝)], categoryList=[CategoryDto(categoryId=24, categoryName=胸心外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=1, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5701, appHits=68, showAppHits=0, pcHits=4296, showPcHits=2029, likes=124, shares=6, comments=4, approvalStatus=1, publishedTime=Fri Jan 26 15:01:20 CST 2018, publishedTimeString=2018-01-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Fri Jan 26 15:01:20 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 11:15:37 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 STS/SCA/AmSECT临床实践指南：心肺转流术期间的抗凝作用)])
2018 STS/SCA/AmSECT临床实践指南：心肺转流术期间的抗凝作用
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=282558, encodeId=14af282558e0, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Sat Jan 27 13:03:31 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282249, encodeId=f1b3282249f3, content=^_^^_^^_^^_^, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Fri Jan 26 17:32:03 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282238, encodeId=3b862822388b, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Jan 26 16:34:52 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282229, encodeId=0d9e2822293c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Fri Jan 26 15:18:32 CST 2018, time=2018-01-26, status=1, ipAttribution=)]
    2018-01-27 1217549fm29暂无昵称

    henhao

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=282558, encodeId=14af282558e0, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Sat Jan 27 13:03:31 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282249, encodeId=f1b3282249f3, content=^_^^_^^_^^_^, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Fri Jan 26 17:32:03 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282238, encodeId=3b862822388b, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Jan 26 16:34:52 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282229, encodeId=0d9e2822293c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Fri Jan 26 15:18:32 CST 2018, time=2018-01-26, status=1, ipAttribution=)]
    2018-01-26 wqkm

    ^_^^_^^_^^_^

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=282558, encodeId=14af282558e0, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Sat Jan 27 13:03:31 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282249, encodeId=f1b3282249f3, content=^_^^_^^_^^_^, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Fri Jan 26 17:32:03 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282238, encodeId=3b862822388b, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Jan 26 16:34:52 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282229, encodeId=0d9e2822293c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Fri Jan 26 15:18:32 CST 2018, time=2018-01-26, status=1, ipAttribution=)]
    2018-01-26 Y—xianghai

    学习了新知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=282558, encodeId=14af282558e0, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Sat Jan 27 13:03:31 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282249, encodeId=f1b3282249f3, content=^_^^_^^_^^_^, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Fri Jan 26 17:32:03 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282238, encodeId=3b862822388b, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Jan 26 16:34:52 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282229, encodeId=0d9e2822293c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Fri Jan 26 15:18:32 CST 2018, time=2018-01-26, status=1, ipAttribution=)]
    2018-01-26 happsf

    学习

    0